These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 10712086)

  • 1. [Care for life. Central is the patient].
    Hilpert U
    Internist (Berl); 2000 Jan; 41(1):A37. PubMed ID: 10712086
    [No Abstract]   [Full Text] [Related]  

  • 2. Improving outcome in acute coronary syndromes - as good as it gets?
    Purcell H; Fox KM
    Eur Heart J; 1999 Nov; 20(21):1533-7. PubMed ID: 10529321
    [No Abstract]   [Full Text] [Related]  

  • 3. [Long-term administration of Dalteparin in unstable coronary syndrome. FRISC II study opens novel therapeutic perspectives. Fragmin and Fast Revascularization during Instability in Coronary Artery Disease].
    Arnheim K
    Internist (Berl); 2000 Jan; 41(1):A35-6. PubMed ID: 10712085
    [No Abstract]   [Full Text] [Related]  

  • 4. [1999 Robert Koch Drug Award for enoxaparin. Safely preventing thromboembolism].
    Stiefelhagen P
    MMW Fortschr Med; 1999 Sep; 141(38):18. PubMed ID: 10904611
    [No Abstract]   [Full Text] [Related]  

  • 5. Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes.
    ; Mehta SR; Yusuf S; Granger CB; Wallentin L; Peters RJ; Bassand JP; Budaj A; Joyner C; Chrolavicius S; Fox KA
    Am Heart J; 2005 Dec; 150(6):1107. PubMed ID: 16338245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library.
    Petersen JL; Mahaffey KW; Becker RC; Goodman SG; Kleiman NS; Marian AJ; Stone GW; Lansky AJ; Lincoff AM; Hazen SL; Nessel CC; Toro-Figueroa L; Tate L; Reist CJ; Cohen M; Califf RM; Ferguson JJ;
    Am Heart J; 2004 Aug; 148(2):269-76. PubMed ID: 15308996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prior aspirin users with acute non-ST-elevation coronary syndromes are at increased risk of cardiac events and benefit from enoxaparin.
    Santopinto J; Gurfinkel EP; Torres V; Marcos E; Bozovich GE; Mautner B; McCabe CH; Antman EM
    Am Heart J; 2001 Apr; 141(4):566-72. PubMed ID: 11275921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Home treatment of deep venous thrombosis.
    Force RW
    J Fam Pract; 1996 Jun; 42(6):566-7. PubMed ID: 8656163
    [No Abstract]   [Full Text] [Related]  

  • 9. [Stroke. Enoxaparin sodium inhibits venous thromboembolism compared to unfractionated heparin].
    Drossbach M
    Med Monatsschr Pharm; 2007 Nov; 30(11):426. PubMed ID: 18062340
    [No Abstract]   [Full Text] [Related]  

  • 10. [A multicenter cooperative study on prevention and treatment of unstable angina associated with acute myocardial infarction and cardiac death].
    Zhonghua Xin Xue Guan Bing Za Zhi; 1993 Apr; 21(2):77-9. PubMed ID: 8223166
    [No Abstract]   [Full Text] [Related]  

  • 11. Enoxaparin in acute coronary syndromes.
    Lee S; Gibson CM
    Expert Rev Cardiovasc Ther; 2007 May; 5(3):387-99. PubMed ID: 17489664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of venous and cardiovascular thrombosis: enoxaparin.
    Harvey DM; Offord RH
    Hosp Med; 2000 Sep; 61(9):628-36. PubMed ID: 11048604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapy of unstable angina with the low molecular weight heparins.
    Ageno W; Turpie AG
    Vasc Med; 2000; 5(4):217-23. PubMed ID: 11213233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A simple, readily available method for risk stratification of patients with unstable angina and non-ST elevation myocardial infarction.
    Holper EM; Antman EM; McCabe CH; Premmereur J; Gurfinkel E; Bernink PJ; Turpie AG; Bayes de Luna A; Lablanche JM; Fox KM; Salein D; Radley DR; Braunwald E
    Am J Cardiol; 2001 Apr; 87(8):1008-10; A5. PubMed ID: 11305997
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of enoxaparin and unfractionated heparin on thrombin generation in acute coronary syndromes without ST-segment elevation.
    Salvioni A; Casilli F; Assanelli E; Grazi M; Marenzi G; Guazzi MD
    Thromb Haemost; 2001 Oct; 86(4):991-4. PubMed ID: 11686357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non-ST-elevation acute coronary syndromes.
    Califf RM; Petersen JL; Hasselblad V; Mahaffey KW; Ferguson JJ
    Am Heart J; 2005 Apr; 149(4 Suppl):S91-9. PubMed ID: 16124953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiplatelet drugs in cardiovascular prevention: coronary events: acute phase and secondary prevention.
    Prescrire Int; 2000 Jun; 9(47):83-5. PubMed ID: 11010749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-molecular-weight heparin and platelet glycoprotein IIb/IIIa receptor blockade in the treatment of acute coronary syndromes: complementary or competing therapies?
    White HD
    J Invasive Cardiol; 2000 Feb; 12 Suppl A():6A-13A. PubMed ID: 10731290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost prediction models for the comparison of two groups.
    Willan AR; O'Brien BJ
    Health Econ; 2001 Jun; 10(4):363-6. PubMed ID: 11400259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year follow-up of TIMI 11B and ESSENCE.
    Antman EM; Cohen M; McCabe C; Goodman SG; Murphy SA; Braunwald E;
    Eur Heart J; 2002 Feb; 23(4):308-14. PubMed ID: 11812067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.